| Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell–directed therapies P Ghione, JJ Gu, K Attwood, P Torka, S Goel, S Sundaram, C Mavis, ... Blood, The Journal of the American Society of Hematology 138 (9), 811-814, 2021 | 110 | 2021 |
| Display screen with a graphical user interface PJ Hoffman, JM Considine, MA Johnson, M Babic, AC Suralta, ... US Patent App. 29/599,197, 2019 | 69 | 2019 |
| Spontaneous bacterial empyema: not your average empyema ST Lam, ML Johnson, RM Kwok, JT Bassett The American journal of medicine 127 (7), e9-e10, 2014 | 17 | 2014 |
| Phase 3 randomized, double-blind, sham-controlled Trial of e-TNS for the Acute treatment of Migraine (TEAM) DE Kuruvilla, JI Mann, SJ Tepper, AJ Starling, G Panza, MAL Johnson Scientific reports 12 (1), 5110, 2022 | 13 | 2022 |
| Near SUDEP during bilateral stereo‐EEG monitoring characterized by diffuse postictal EEG suppression M Johnson, N Samudra, MJ Gallagher, B Abou‐Khalil, WP Nobis Epilepsia 62 (4), e60-e64, 2021 | 12 | 2021 |
| Management of acute concussion in a deployed military setting MAL Johnson, JS Hawley, BJ Theeler Current treatment options in neurology 16, 1-16, 2014 | 7 | 2014 |
| Unihemispheric cerebral vasculitis: case report and review of literature MAL Johnson, GA Jakubek, JS Hawley Journal of the Neurological Sciences 368, 32-34, 2016 | 6 | 2016 |
| Carfilzomib combined with rituximab, ifosfamide, carboplatin, and etoposide for relapsed or refractory DLBCL P Torka, A Groman, J Wong, J Nichols, A Kader, C Mavis, ... Blood Advances 7 (7), 1146-1155, 2023 | 4 | 2023 |
| Ofatumumab plus HyperCVAD/HD‐MA induction leads to high rates of minimal residual disease negativity in patients with newly diagnosed mantle cell lymphoma: Results of a phase 2 … P Torka, OS Akhtar, NM Reddy, BE Baysal, A Kader, A Groman, J Nichols, ... Cancer 128 (8), 1595-1604, 2022 | 3 | 2022 |
| Tourette syndrome JS Hawley, MA Johnson, DH Dennison Succinct pediatrics: evaluation and management for newborn, genetic …, 2018 | 3 | 2018 |
| Retrospective analysis of nurse-administered fall assessment scales in the Epilepsy Monitoring Unit MAL Johnson, A Boudreaux, B Abou-Khalil Epilepsy & Behavior 140, 109080, 2023 | 2 | 2023 |
| The Use of Rituximab in Neurological Diseases; Real World Data from a Neuroscience Centre (2575) A Kondratiuk, P Muraro, M Johnson, V Sing-Curry, J Pritchard, R Dorsey, ... Neurology 94 (15_supplement), 2575, 2020 | 1 | 2020 |
| Extranet-based transaction services network SB Millhouse, CG Busch, NT Gilman, SM Porter, PJ Hoffman, J Wong, ... US Patent App. 15/475,678, 2018 | 1 | 2018 |
| Dashboard patient self service product enhancement PJ Hoffman, JM Considine, MA Johnson, M Babic, KO Horvath, ... US Patent App. 15/474,892, 2018 | 1 | 2018 |
| From Army-Navy to the NFL: The Evolution of the Football Helmet (IN5-1.007) M Johnson, M Etienne Neurology 80 (7_supplement), IN5-1.007-IN5-1.007, 2013 | 1 | 2013 |
| Carfilzomib plus rituximab, ifosfamide, carboplatin and etoposide (C-RICE) led to higher response, OS, and PFS in patients with transplant-eligible relapsed or refractory (R/R … M Amin, A Niu, K Attwood, A George, F Azad, J Wong, G Schofield, ... Journal of Clinical Oncology 42 (16_suppl), 7042-7042, 2024 | | 2024 |
| P2. 08-02 STAR-121: Phase 3 Study of DOM and ZIM plus Chemo vs Pembro plus Chemo in 1L mNSCLC with No Actionable Gene Alterations D Rodriguez-Abreu, J Bosch-Barrera, JE Gray, MJ Ahn, M Johnson, X Yu, ... Journal of Thoracic Oncology 18 (11), S328, 2023 | | 2023 |
| Actualisation des données de phase I de recherche de dose et premières données de la phase d’expansion du tarlatamab, un anticorps bispécifique ciblant la protéine DLL3 et … S Champiat, H Izumi, M Johnson, H Borghaei, T Owonikoko, V Lai, ... Revue des Maladies Respiratoires Actualités 15 (1), 127-128, 2023 | | 2023 |
| Temporal intermittent rhythmic theta activity (TIRTA): A marker of epileptogenicity? J Fox, N Samudra, M Johnson, MJ Humayun, BW Abou-Khalil Eneurologicalsci 29, 100433, 2022 | | 2022 |
| External Trigeminal Nerve Stimulation as a Non-pharmacological Option for the Prevention and Acute Treatment of Migraine D Johnson, Michael AL, Kuruvilla touchREVIEWS in Neurology 18 (1), 22-31, 2022 | | 2022 |
Niyatee SamudraVanderbilt University Medical CenterEmail verificata su vumc.org